Search
Tegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedTegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Montelukast
go.drugbank.com/drugs/DB00471ApprovedInvestigationalin individuals who used the medication. … corticosteroids or other agents in asthma step therapy.
Products: GLEMONT IR Tablets 10mg, N-FESS 10 MG FILM TABLET, 90 ADETRitonavir
go.drugbank.com/drugs/DB00503ApprovedInvestigationalAmerican Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for … It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules.
Mixtures: VIRONTAR N COMPRIMIDOS RECUBIERTOS, VIRONTAR N COMPRIMIDOS RECUBIERTOSCategories: Antivirals used in combination for the treatment of HIV infectionsBetaine
go.drugbank.com/drugs/DB06756ApprovedInvestigationalNutraceuticalBetaine is a methyl group donor that functions in the normal metabolic cycle of methionine. … [L43105] Although it is present in many food products, the levels found there are insufficient to treat this condition.
Mixtures: Face It Hd Perfect Bb Spf30 Pa 02, Face It Hd Perfect Bb Spf30 Pa 01Synonyms: 2-N,N,N-trimethylammonio acetate, N,N,N-TrimethylglycineAnastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigational[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863] … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnThe same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line
Products: I-HEP CLASTAVIR 30, I-HEP CLASTAVIR 60Lactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedA normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. … Lactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]
Mixtures: Dextrose in Lactated Ringers, D5-LRI (5% DEXTROSE IN LOCTATED RINGER'S INJ.)Omidenepag isopropyl
go.drugbank.com/drugs/DB15071Approved[A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.
Synonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinateCalcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawn[A31516] This drug was developed by Lederle Cyanamid Canada Inc and approved for marketing in Canada in 1959. The current status of calcium carbimide is cancelled post marketing.[L1113] … Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Alcohol DependencePertussis vaccine
go.drugbank.com/drugs/DB15274ApprovedInvestigationalPertussis vaccine is under investigation in clinical trial NCT01698346 (Pertussis (Tdap) Vaccination in Pregnancy).
Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, dTaP Booster Injektionssuspension in einer Fertigspritze